Cohance Lifesciences Share Price
459.05-2.40 (-0.52%)
-48.96% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
COHANCENSE
Cohance Lifesciences Share Price
459.05-2.40 (-0.52%)
-48.96% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | 18% | 19% | -13% |
| - | -13% | -24% | -69% |
| - | -3% | -5% | -49% |
| 24% | 19% | 12% | 4% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
MANKIND
DRREDDY
AUROPHARMA
LUPIN
COHANCE
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,849.9 | ₹447476 Cr | 37 | 12.07 | 62.82 | ₹11479 Cr |
| 9,602 | ₹254764 Cr | 87.1 | 34.04 | 128.41 | ₹2568 Cr |
| 4,928.5 | ₹189423 Cr | 86.85 | 16.72 | 97.06 | ₹2163 Cr |
| 1,180.3 | ₹116658 Cr | 25.85 | 9.42 | 62.53 | ₹5040 Cr |
| 1,399 | ₹111484 Cr | 33.08 | 9.77 | 57.87 | ₹3879 Cr |
| 2,026.2 | ₹109943 Cr | 100.55 | 6.8 | 29.25 | ₹889 Cr |
| 2,500 | ₹101712 Cr | 49.79 | 13.75 | 71.08 | ₹1913 Cr |
| 1,200.4 | ₹101005 Cr | 31.35 | 5.32 | 63.99 | ₹4196 Cr |
| 1,716 | ₹99253 Cr | 26.73 | 17.95 | 96.84 | ₹3505 Cr |
| 2,100.7 | ₹96031 Cr | 17.37 | 30.95 | 154.35 | ₹5333 Cr |
| 454.15 | ₹17659 Cr | 166.23 | -0.63 | 7.79 | ₹179 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — |
| ₹38 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹13 Cr | ₹0 |
| ₹18 Cr | ₹82 Cr | ₹2 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹13 Cr |
| ₹3855 Cr | ₹3542 Cr | ₹2023 Cr | ₹1710 Cr | ₹1502 Cr | ₹1155 Cr | ₹832 Cr | ₹578 Cr |
| ₹3855 Cr | ₹3542 Cr | ₹2023 Cr | ₹1710 Cr | ₹1502 Cr | ₹1155 Cr | ₹832 Cr | ₹578 Cr |
| ₹3911 Cr | ₹3649 Cr | ₹2051 Cr | ₹1735 Cr | ₹1527 Cr | ₹1181 Cr | ₹845 Cr | ₹590 Cr |
| ₹123 Cr | ₹144 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹50 Cr | ₹130 Cr | ₹0 | ₹5 Cr | ₹28 Cr | ₹36 Cr | ₹0 | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹91 Cr | ₹0 |
| ₹95 Cr | ₹102 Cr | ₹65 Cr | ₹58 Cr | ₹54 Cr | ₹31 Cr | ₹28 Cr | ₹29 Cr |
| ₹901 Cr | ₹750 Cr | ₹21 Cr | ₹70 L | ₹46 L | ₹74 L | ₹51 L | ₹0 |
| ₹40 L | ₹26 L | ₹0 | ₹8 Cr | ₹9 Cr | ₹7 Cr | ₹8 Cr | ₹6 Cr |
| ₹1047 Cr | ₹982 Cr | ₹86 Cr | ₹72 Cr | ₹92 Cr | ₹74 Cr | ₹128 Cr | ₹35 Cr |
| — | — | — | — | — | — | — | — |
| ₹285 Cr | ₹268 Cr | ₹42 Cr | ₹70 Cr | ₹106 Cr | ₹83 Cr | ₹71 Cr | ₹54 Cr |
| ₹223 Cr | ₹313 Cr | ₹21 Cr | ₹20 Cr | ₹30 Cr | ₹29 Cr | ₹28 Cr | ₹19 Cr |
| ₹74 Cr | ₹71 Cr | ₹39 Cr | ₹65 Cr | ₹67 Cr | ₹106 Cr | ₹94 Cr | ₹83 Cr |
| ₹64 Cr | ₹53 Cr | ₹15 Cr | ₹149 Cr | ₹145 Cr | ₹104 Cr | ₹127 Cr | ₹35 Cr |
| ₹646 Cr | ₹705 Cr | ₹117 Cr | ₹303 Cr | ₹348 Cr | ₹322 Cr | ₹320 Cr | ₹191 Cr |
| ₹5727 Cr | ₹5480 Cr | ₹2254 Cr | ₹2110 Cr | ₹1967 Cr | ₹1576 Cr | ₹1292 Cr | ₹816 Cr |
| ₹53 Cr | ₹58 Cr | ₹18 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹10 Cr | ₹11 Cr |
| ₹170 Cr | ₹258 Cr | ₹39 Cr | ₹69 Cr | ₹96 Cr | ₹141 Cr | ₹185 Cr | ₹83 Cr |
| — | — | — | — | — | — | — | — |
| ₹4231 Cr | ₹3788 Cr | ₹929 Cr | ₹876 Cr | ₹694 Cr | ₹570 Cr | ₹457 Cr | ₹347 Cr |
| ₹862 Cr | ₹681 Cr | ₹260 Cr | ₹212 Cr | ₹160 Cr | ₹128 Cr | ₹100 Cr | ₹77 Cr |
| ₹3369 Cr | ₹3107 Cr | ₹670 Cr | ₹663 Cr | ₹534 Cr | ₹441 Cr | ₹357 Cr | ₹271 Cr |
| ₹173 Cr | ₹332 Cr | ₹179 Cr | ₹165 Cr | ₹30 Cr | ₹96 Cr | ₹102 Cr | ₹111 Cr |
| ₹262 Cr | ₹145 Cr | ₹131 Cr | ₹117 Cr | ₹117 Cr | ₹361 Cr | ₹307 Cr | ₹7 L |
| ₹262 Cr | ₹145 Cr | ₹131 Cr | ₹117 Cr | ₹117 Cr | ₹361 Cr | ₹307 Cr | ₹7 L |
| ₹71 Cr | ₹86 Cr | ₹22 Cr | ₹9 Cr | ₹13 Cr | ₹11 Cr | ₹15 Cr | ₹11 Cr |
| ₹19 Cr | ₹13 Cr | ₹0 | ₹0 | ₹7 Cr | ₹16 L | ₹20 L | ₹22 L |
| ₹3899 Cr | ₹3687 Cr | ₹1001 Cr | ₹955 Cr | ₹702 Cr | ₹910 Cr | ₹781 Cr | ₹393 Cr |
| — | — | — | — | — | — | — | — |
| ₹266 Cr | ₹192 Cr | ₹774 Cr | ₹419 Cr | ₹481 Cr | ₹181 Cr | ₹31 Cr | ₹7 Cr |
| ₹562 Cr | ₹467 Cr | ₹231 Cr | ₹313 Cr | ₹283 Cr | ₹201 Cr | ₹175 Cr | ₹157 Cr |
| ₹681 Cr | ₹772 Cr | ₹134 Cr | ₹111 Cr | ₹236 Cr | ₹102 Cr | ₹117 Cr | ₹148 Cr |
| ₹60 Cr | ₹102 Cr | ₹51 Cr | ₹68 Cr | ₹47 Cr | ₹10 Cr | ₹14 Cr | ₹13 Cr |
| ₹42 Cr | ₹33 Cr | ₹12 Cr | ₹11 Cr | ₹11 Cr | ₹12 Cr | ₹9 Cr | ₹13 Cr |
| ₹185 Cr | ₹192 Cr | ₹52 Cr | ₹233 Cr | ₹206 Cr | ₹161 Cr | ₹165 Cr | ₹85 Cr |
| ₹1796 Cr | ₹1758 Cr | ₹1253 Cr | ₹1155 Cr | ₹1265 Cr | ₹667 Cr | ₹511 Cr | ₹423 Cr |
| ₹1150 Cr | ₹1053 Cr | ₹1136 Cr | ₹852 Cr | ₹918 Cr | ₹345 Cr | ₹191 Cr | ₹232 Cr |
| ₹5727 Cr | ₹5480 Cr | ₹2254 Cr | ₹2110 Cr | ₹1967 Cr | ₹1576 Cr | ₹1292 Cr | ₹816 Cr |
| ₹102 | ₹140 | ₹80 | ₹68 | ₹60 | ₹46 | ₹66 | ₹0 |
| ₹102 | ₹140 | ₹80 | ₹68 | ₹60 | ₹46 | ₹33 | ₹0 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|
| ₹207 Cr | ₹643 Cr | ₹406 Cr | ₹560 Cr | ₹668 Cr | ₹468 Cr | ₹405 Cr | ₹158 Cr |
| ₹208 Cr | ₹207 Cr | ₹17 Cr | ₹37 Cr | ₹41 Cr | ₹36 Cr | ₹35 Cr | ₹14 Cr |
| ₹21 Cr | -₹73 L | ₹72 Cr | ₹6 Cr | -₹194 Cr | -₹12 Cr | ₹54 Cr | -₹88 Cr |
| ₹436 Cr | ₹849 Cr | ₹495 Cr | ₹603 Cr | ₹514 Cr | ₹492 Cr | ₹493 Cr | ₹83 Cr |
| ₹368 Cr | ₹673 Cr | ₹385 Cr | ₹457 Cr | ₹330 Cr | ₹383 Cr | ₹407 Cr | ₹50 Cr |
| -₹255 Cr | -₹390 Cr | -₹362 Cr | -₹195 Cr | -₹136 Cr | -₹311 Cr | -₹413 Cr | -₹65 Cr |
| -₹165 Cr | -₹327 Cr | -₹40 Cr | -₹242 Cr | -₹156 Cr | -₹76 Cr | ₹7 Cr | ₹26 Cr |
| -₹51 Cr | -₹44 Cr | -₹18 Cr | ₹20 Cr | ₹37 Cr | -₹5 Cr | ₹79 L | ₹11 Cr |
| ₹97 Cr | ₹138 Cr | ₹65 Cr | ₹45 Cr | ₹7 Cr | ₹12 Cr | ₹11 Cr | ₹0 |
| ₹4 Cr | ₹2 Cr | ₹0 | ₹0 | ₹4,000 | ₹3,000 | ₹6,000 | ₹0 |
| ₹49 Cr | ₹97 Cr | ₹47 Cr | ₹65 Cr | ₹45 Cr | ₹7 Cr | ₹12 Cr | ₹11 Cr |
Fundamental Ratios
Consolidated
Standalone
Cohance Lifesciences Share Price
459.05-2.40 (-0.52%)
-48.96% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 4
Bearish signals: 2 out of 9 oscillators
RSI
55.26Buy
STOCH %K
64.88Neutral
MACD Level(12,26)
1.58Buy
Ultimate Oscillator
50.25Buy
Aroon Oscillator
38.00Sell
BOP
0.01Buy
CCI
67.48Neutral
Williams %R
-35.12Neutral
Momentum
-1.80Sell
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 8
Bearish signals: 1 out of 9 moving averages
EMA 9
451.21Buy
SMA 9
445.38Buy
EMA 21
449.14Buy
SMA 21
450.29Buy
EMA 50
445.21Buy
SMA 50
444.66Buy
EMA 200
500.89Sell
SMA 200
418.50Buy
WMA 20
448.53Buy
Pivot
Pivot
Classic
Resistance 5
516.80
Resistance 4
502.45
Resistance 3
488.10
Resistance 2
473.75
Resistance 1
467.60
Pivot
459.40
Support 1
453.25
Support 2
445.05
Support 3
430.70
Support 4
416.35
Support 5
402.00
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Cohance Lifesciences Share Price
459.05-2.40 (-0.52%)
-48.96% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| 57.49% | 57.49% | 57.49% | 57.49% | 66.41% | 50.10% |
| 6.50% | 5.59% | 6.01% | 6.51% | 7.23% | 11.05% |
| 1.88% | 3.22% | 4.21% | 4.32% | 2.50% | 3.56% |
| 18.21% | 18.57% | 17.36% | 16.49% | 8.90% | 13.04% |
| 15.92% | 15.13% | 14.93% | 15.19% | 14.96% | 22.25% |
Bulk & block deals
Name
Jasub Property Holdings Llp
Jasti Family Trust
Jasub Property Holdings Llp
Jasti Family Trust
Jasub Property Holdings Llp
Jasti Family Trust
Jasub Property Holdings Llp
Jasti Family Trust
Bnp Paribas Financial Markets
Morgan Stanley Asia (Singapore) Pte.
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 23 Feb 2026 | Purchase | 235.62 Cr | ₹306 | 77 L | Bulk | 2.01256 | NSE |
| 23 Feb 2026 | Sell | 235.62 Cr | ₹306 | 77 L | Bulk | 2.01256 | NSE |
| 23 Feb 2026 | Purchase | 235.62 Cr | ₹306 | 77 L | Block | 2.01256 | NSE |
| 23 Feb 2026 | Sell | 235.62 Cr | ₹306 | 77 L | Block | 2.01256 | NSE |
| 18 Feb 2026 | Purchase | 216.30 Cr | ₹309 | 70 L | Bulk | 1.8296 | NSE |
| 18 Feb 2026 | Sell | 216.30 Cr | ₹309 | 70 L | Bulk | 1.8296 | NSE |
| 18 Feb 2026 | Purchase | 216.30 Cr | ₹309 | 70 L | Block | 1.8296 | NSE |
| 18 Feb 2026 | Sell | 216.30 Cr | ₹309 | 70 L | Block | 1.8296 | NSE |
| 23 Oct 2025 | Purchase | 10.02 Cr | ₹890.75 | 1.12 L | Block | 0.029402 | BSE |
| 23 Oct 2025 | Sell | 10.02 Cr | ₹890.75 | 1.12 L | Block | 0.029402 | BSE |
Insider trading & SAST
Client name
Dsp Trustee Pvt Ltd
Jusmiral Holdings Limited
Jusmiral Holdings Limited
Jasti Property & Equity Holdings Pvt Ltd & Others
Jasti Property & Equity Holdings Pvt Ltd & Others
Jasub Property Holdings Llp & Pacs
Jusmiral Holdings Ltd & Pacs
Jusmiral Holdings Limited
Jusmiral Holdings Limited
Dr. Venkata Naga Kali Vara Prasada Raju Vetukuri
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25 Aug 2026 | Other | Disposal | 0.76 | 3.53 | 0 | — | 29 L | 07 Aug 2026 | Market | 1,34,97,073 | SAST | 29(2) | — |
| 09 Jul 2026 | Promoter | Others | — | — | 0 | — | 8.04 Cr | 17 Jun 2026 | Creation | 8,04,34,990 | SAST | Reg31 | — |
| 30 Jun 2026 | Promoter | Others | — | — | 0 | — | 9.24 Cr | 16 Jun 2026 | Release | 0 | SAST | Reg31 | — |
| 12 Mar 2026 | Other | Disposal | 2.01 | 6.36 | 0 | — | 77 L | 23 Feb 2026 | Inter-se Transfer | 2,43,26,009 | SAST | 29(2) | — |
| 09 Mar 2026 | Other | Disposal | 2.06 | 4.53 | 0 | — | 78.77 L | 18 Feb 2026 | Market | 1,73,16,009 | SAST | 29(2) | — |
| 09 Mar 2026 | Other | Acquisition | 1.83 | 1.83 | 0 | — | 70 L | 18 Feb 2026 | Inter-se Transfer | 70,00,000 | SAST | 29(1) | — |
| 01 Oct 2025 | Promoter | Disposal | 8.93 | 57.49 | 0 | — | 3.41 Cr | 18 Sep 2025 | Market | 21,99,30,170 | SAST | 29(2) | — |
| 23 Sep 2025 | Promoter | Others | — | — | 0 | — | 3.41 Cr | 18 Sep 2025 | Release | 9,23,90,578 | SAST | Reg31 | — |
| 19 Sep 2025 | Promoter | Disposal | 8.926016 | 24.15 | 3,093.81 Cr | ₹906 | 3.41 Cr | 18 Sep 2025 | Market Sale | 9,23,90,578 | Insider Trading | — | Equity Shares |
| 28 Aug 2025 | Director | Disposal | 0.156835 | 0.03 | 52.82 Cr | ₹880.30 | 6 L | 26 Aug 2025 | Market Sale | 1,13,259 | Insider Trading | — | Equity Shares |
Cohance Lifesciences Share Price
459.05-2.40 (-0.52%)
-48.96% past 1 Year
Cohance Lifesciences is a fully integrated global CDMO, partnering with leading innovators across the entire product lifecycle- from route scouting and early development to commercial manufacturing. With advanced capabilities in
Corporate Actions
Date
Type
Details
Company details
Cohance Lifesciences Share Price
459.05-2.40 (-0.52%)
-48.96% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Cohance Lifesciences Share Price
459.05-2.40 (-0.52%)
-48.96% past 1 Year
News
Cohance Lifesciences says Jaggaiahpet API facility cleared USFDA inspection with observations
Equity
COHANCE
Cohance Lifesciences gets USFDA Form 483 observations, begins remediation at plant
Equity
COHANCE
Cohance Lifesciences to host analyst and investor meeting on September 1
Equity
COHANCE
Cohance Lifesciences sees Rs 46.35 crore BSE block trade at Rs 463.5
Equity
COHANCE
Goldman Sachs retains Buy on Cohance, sees recovery from Q2FY27
Equity
COHANCE
Cohance Lifesciences gets US FDA 483 with five observations at Hyderabad facility
Equity
COHANCE
Cohance Lifesciences Q1 EBITDA collapses sharply with margin erosion year-on-year
Equity
COHANCE
Cohance Lifesciences reports lower Q1 revenue at Rs 422 crores
Equity
COHANCE
Cohance Lifesciences narrows Q1 consolidated net loss on yearly basis
Equity
COHANCE
Jefferies Downgrades Cohance Life to Underperform, Cuts Target to Rs 300 on Weak Q4, Management Churn.
Equity
COHANCE
Cohance Lifesciences - Quaterly Results
Equity
COHANCE
Cohance Lifesciences Q4 EBITDA Declines to Rs 98.50 Crores, Margin Contracts to 15.92%
Equity
COHANCE
Cohance Lifesciences Q4 Results: Sharp YoY Profit and Revenue Decline
Equity
COHANCE
Cohance Lifesciences reports Profit after tax of 34.56 Crores, in the March 2026 quarter
Equity
COHANCE
Cohance Lifesciences informs about press release
Equity
COHANCE
Cohance Lifesciences Appoints Former Cipla CEO Umang Vohra as Executive Chairman & Group CEO.
Equity
COHANCE
Cohance Lifesciences Sees Rs 216 Cr Block Deal for 1.83% Stake, Shares Rally 11%.
Equity
COHANCE
Cohance Lifesciences informs about investor conference
Equity
COHANCE
Cohance Life Sciences Rs 207.89 Cr NSE Block Trade for 67.28 Lakh Shares at Rs 309.
Equity
COHANCE
Cohance Lifesciences Reaffirms Mid-Term Margin Guidance of 30%+ Amid Current Pressures.
Equity
COHANCE

